|Dr. Osamu Okuda||Pres, CEO & Representative Director||584.78k||N/A||1963|
|Mr. Motoo Ueno||Deputy Chairman||689.51k||N/A||N/A|
|Mr. Toshiaki Itagaki||CFO & EVP - Fin. & Acct., Corp. Comm., Purchasing, Dig. Strategy & IT Sol and Head of Fin. Sup. Div.||N/A||N/A||N/A|
|Toshiya Sasai||Exec. of Investor Relations Group & Corp. Communications Department||N/A||N/A||N/A|
|Masahiko Uchida||Gen. Mang. of Corp. Communications Department||N/A||N/A||N/A|
|Mr. Shinji Hidaka||VP & Head of Marketing & Sales Division||N/A||N/A||N/A|
|Mr. Tsunanori Sato||VP and GM of Marketing & Sales Division||N/A||N/A||N/A|
|Mr. Yoshiyuki Yano||VP & Head of HR Management Department||N/A||N/A||N/A|
|Mr. Shinya Unno||Deputy Pres||N/A||N/A||N/A|
|Mr. Junichi Ebihara||Exec. VP||N/A||N/A||N/A|
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.
Chugai Pharmaceutical Co., Ltd.’s ISS governance QualityScore as of 26 September 2021 is 4. The pillar scores are Audit: 1; Board: 5; Shareholder rights: 8; Compensation: 1.